Silicon Valley has been trying to run a mile from the mess that is Theranos. But the debacle at the blood-testing start-up - which the US Securities and Exchange Commission said this week was a "massive fraud" - will not be as easy to shrug off as the powers-that-be in the tech world would like.
It also holds a particular warning at a time when tech start-ups are extending their reach into industries from healthcare to finance and transportation.
We have been experiencing some problems with subscriber log-ins and apologise for the inconvenience caused. Until we resolve the issues, subscribers need not log in to access ST Digital articles. But a log-in is still required for our PDFs.